Oil prices edge down from one-month high with upcoming OPEC+ meeting in focus
In recent transactions reported to the Securities and Exchange Commission, Scholar Rock Holding Corp ’s (NASDAQ:SRRK) Chief Human Resources Officer, Caryn Parlavecchio, has sold a portion of her holdings in the company. On February 18, 2025, Parlavecchio sold 5,296 shares of common stock at an average price of $36.829 per share, totaling approximately $195,046. The transaction comes amid Scholar Rock’s impressive 307% surge over the past six months, with the stock currently trading at $39.15, giving the company a market capitalization of $3.65 billion.
The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units (RSUs), as mandated by Scholar Rock’s equity incentive plans. This transaction was not a discretionary trade by Parlavecchio. Following this sale, she retains ownership of 140,258 shares, which includes 58,469 shares of common stock and 81,789 RSUs.
This transaction highlights the structured approach companies take in managing equity compensation and related tax obligations for their executives. For deeper insights into insider trading patterns and comprehensive financial analysis, including 12 additional ProTips, check out the detailed Scholar Rock research report on InvestingPro.
In other recent news, Scholar Rock has submitted a Biologics License Application to the U.S. FDA for apitegromab, a therapy aimed at improving motor function in individuals with spinal muscular atrophy (SMA). The application is supported by positive results from the Phase 3 SAPPHIRE trial, which showed statistically significant improvements in motor function. Scholar Rock is also preparing to submit a Marketing Authorization Application to the European Medicines Agency in early 2025. Meanwhile, the company is advancing its cardiometabolic program with a Phase 2 trial in obesity, expected to yield data by mid-2025.
Analysts have adjusted their outlook on Scholar Rock following these developments. H.C. Wainwright increased the price target for the company to $50.00, maintaining a Buy rating, citing reduced competition after a competing SMA drug failed a Phase 3 trial. Truist Securities also raised its price target to $45.00, reflecting increased confidence in apitegromab’s market potential. The analysts project peak sales for apitegromab to reach up to $1.5 billion, driven by the reduced competitive landscape and positive trial outcomes.
Scholar Rock’s financial position remains strong, with sufficient funds to support its operations into late 2026. The company is also expanding its research efforts with a new Phase 2 OPAL trial for younger SMA patients set to begin in mid-2025. These strategic moves indicate Scholar Rock’s commitment to broadening the applications of apitegromab and exploring new therapeutic areas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.